The decision an active patient actually faces

Faced with a focal cartilage defect and an active life, most patients ask the same question: does it matter which repair procedure they choose? The short answer, at two years, is often no — both osteochondral autograft transfer (OATS) and microfracture can produce acceptable pain relief and a credible return to sport, and early follow-up data rarely separate them convincingly. The answer over a sporting career, however, is clear.

The Gudas et al. prospective randomised controlled trial — the only trial in young athletes to reach a genuine ten-year endpoint — found treatment failure in 14% of patients who had OATS and 38% of those who had microfracture, a statistically significant difference. Return-to-sport rates at ten years followed the same direction: 84–100% with OATS against 44–83% with microfracture, with microfracture athletes more likely to be competing at a reduced level or to have retired from sport altogether.

The question an active patient is really asking, then, is not which procedure works but which one holds up. Over ten years, in athletic populations, the evidence points consistently in one direction. The sections below explain why the gap opens, when it opens, and what determines whether OATS is the appropriate choice for a given patient.

Why repair tissue type is the mechanical fault line

The divergence in long-term outcomes has a straightforward biological explanation, and it starts the moment each procedure is completed.

Microfracture works by drilling small channels through the cartilage into the bone beneath, allowing blood and marrow-derived stem cells to seep up and form a clot. That clot matures into fibrocartilage — a repair tissue that fills the defect but is structurally distinct from the hyaline cartilage it replaces. Fibrocartilage is softer, less stiff, and considerably more prone to wear under repetitive load. Think of it as filling a pothole with a temporary surface compound rather than relaying the road with the original material: adequate for light use, but not engineered for the forces that follow. In active patients, fibrocartilage breakdown may begin as early as two to three years after surgery, and the drilling process itself can disrupt the subchondral bone plate — the structural layer underneath cartilage — making any subsequent repair procedure more technically difficult.

OATS takes a different approach entirely. Cylindrical plugs of bone and cartilage are harvested from a low-load region of the patient's own knee and press-fitted into the defect site. The cartilage on those plugs is genuine hyaline cartilage — the same tissue that lines a healthy joint — and it arrives with its subchondral bone base intact. Under the pivoting, high-impact demands of athletic activity, that structural integrity is not a cosmetic advantage; it is what allows the repair to distribute load correctly across years rather than months.

The two-year trap: why early results mislead

Solheim et al.'s long-term cohort — 119 microfracture patients and 84 who had mosaicplasty/OAT — provides the clearest illustration of when the performance gap actually opens. Microfracture survival dropped below 80% within the first 12 months and below 60% within three years (log-rank P<0.001). OAT survival, by contrast, held above 80% for the first seven years and above 60% at fifteen. Mean time to failure was 4.0 years with microfracture against 8.4 years with OAT.

That 4.0-year average sits squarely beyond the two-year mark that most registry entries and short follow-up studies capture — which is the practical problem with early-horizon data. A patient or peer describing a successful microfracture at one or two years is reporting from inside the period before failure has accumulated. Studies with a two- to three-year endpoint are in the same position: they capture the window when the survival curves still overlap, not the period that determines whether a repair sustains athletic participation across a career.

Short-term data are not wrong — they are just answering a different question. For an active patient deciding between procedures at age 25 or 35, the clinically meaningful standard is ten-year endpoint evidence, because that is the timeframe over which the distinction between the two techniques actually expresses itself.

What the durability numbers show at 10 and 15 years

Those Solheim survival figures do not stand alone. A 2024 network meta-analysis by Muthu et al., drawing on multiple independent datasets, reached the same conclusion: OAT produced significantly better long-term functional outcomes at ten years compared with marrow stimulation — a finding that holds up even when heterogeneous study designs and varying outcome measures are pooled together. When a single-centre cohort and a network meta-analysis converge, the direction of evidence is hard to dismiss.

Gudas's group, whose original randomised trial forms the foundation of this comparison, extended follow-up to fifteen to seventeen years and found that the superiority of mosaicplasty over microfracture remained intact across that horizon — suggesting the durability advantage is not a mid-term artefact that eventually equalises, but a sustained structural difference in how the repair tissue holds up across a sporting career.

The most vivid illustration of the long-term attrition problem with microfracture comes from a 2025 cohort of fifty elite athletes — perhaps the most favourable possible patient group for the procedure, given their conditioning and structured rehabilitation. Ninety-four per cent returned to play within a mean of 9.3 months: an impressive early figure. Yet by five years, only 54.5% were still playing. Larger lesions, exceeding 2 cm in diameter, significantly reduced both the initial return rate and participation at the five-year mark. In competitive sport, a procedure that gets most athletes back quickly but loses nearly half of them within five years is not performing as a durable solution.

When OATS is the right fit — and when it is not

All of this applies most forcefully to a specific patient profile: active and sport-playing, with a contained focal defect. The evidence underpinning OATS's advantage was built in athletic cohorts, and this matters when applying it clinically. In general mixed-activity or non-athletic populations, studies have not found a statistically significant difference in outcomes between OATS and microfracture at comparable follow-up — the divergence is driven by the mechanical demands sport places on repair tissue, not diagnosis alone. For less active patients, the case for accepting OATS's additional procedural complexity is correspondingly weaker.

Lesion size is the second sorting variable. Microfracture failure accelerates considerably for defects approaching or exceeding 2.5–3 cm²; OATS maintains structural integrity across medium-to-large contained defects, and the multi-plug mosaicplasty configuration can address areas up to approximately 4 cm².

OATS carries genuine trade-offs. Harvesting an osteochondral plug from the peripheral femoral condyle introduces donor-site morbidity — pain, stiffness, and the risk of a localised secondary defect — that does not arise with microfracture. The procedure is also technically more demanding, which partly explains a striking UK audit finding: across 19 centres over five years, just 29 OATS procedures were recorded against 1,579 microfractures, with fewer than half of centres performing the technique at all. That gap reflects training and resource constraints rather than deliberate clinical preference, and it means some eligible patients may not have been offered the option.

For anyone who has already undergone microfracture, the practical implication is that earlier specialist review is worth pursuing — the window for certain revision procedures narrows over time, so the sooner an assessment happens, the broader the choices that remain open.

Getting an informed assessment in London

The ten-year evidence strongly favours OATS for active patients with contained focal defects, but no single metric determines the right choice. Lesion size, ICRS grade, whether prior marrow stimulation has altered the subchondral bone plate, activity demand, and what imaging actually shows about repair-tissue quality all feed into the decision — as does which techniques the operating surgeon can reliably deliver.

For patients who have already had microfracture, the most important question to raise with a specialist is how the repair tissue looks on current MRI and whether the subchondral architecture is still intact, because the window for certain revision pathways narrows as that layer degrades. For those approaching a first procedure, it is worth asking specifically whether OATS, AMIC, or a cell-based option such as MACI has been considered and, if not, what the clinical reasoning is — given that short-term outcome data rarely separate the techniques and the meaningful divergence only becomes visible past five years.

A cartilage-specific MRI sequence rather than standard knee imaging is the minimum prerequisite for a defensible assessment. At the London Cartilage Clinic on Harley Street, Professor Paul Y. F. Lee leads specialist cartilage assessment and surgical planning across this full range of options for active patients. Further information and consultation bookings are available at londoncartilage.com.

1. [1] Evaluating single-stage cartilage treatments in the knee: systematic review of OATS and minced cartilage repair. (2026). https://doi.org/10.1016/j.jor.2025.12.052 https://doi.org/10.1016/j.jor.2025.12.052
2. [2] Treatment options and outcomes for paediatric knee cartilage lesions: a systematic review. (2025). https://doi.org/10.1016/j.knee.2025.08.020 https://doi.org/10.1016/j.knee.2025.08.020
3. [3] Long-Term Survival after Microfracture and Mosaicplasty for Knee Articular Cartilage Repair: A Comparative Study Between Two Treatments Cohorts. (2018). https://doi.org/10.1177/1947603518783482 https://doi.org/10.1177/1947603518783482
4. [4] Management of cartilage defects of the knee and injection therapy: UK collaborative study. (2025). https://doi.org/10.1016/j.knee.2025.11.013 https://doi.org/10.1016/j.knee.2025.11.013
5. [5] Microfracture for full-thickness chondral lesions in elite athletes: return-to-play rates. (2025). https://doi.org/10.1002/ksa.12808 https://doi.org/10.1002/ksa.12808